6533b827fe1ef96bd128727c

RESEARCH PRODUCT

High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells

Ingo G.h. Schmidt-wolfFrancesca Garofano

subject

Cytotoxicity ImmunologicAdoptive cellular immunotherapyEndocannabinoid systemcytokine-induced killer cellsCD3Multiple myeloma.Plasma cellPeripheral blood mononuclear cellArticleCatalysisReceptor Cannabinoid CB2lcsh:ChemistryInorganic ChemistryImmune systemCell Line TumormedicineHumansCannabidiolCytotoxic T cellPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyCells CulturedSpectroscopyCytokine-induced killer cellbiologyChemistryOrganic ChemistryGeneral MedicineComputer Science Applicationsmultiple myelomaHaematopoiesisCytokine-induced killer cellmedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Cancer researchbiology.proteinBone marrow

description

Multiple myeloma (MM) is characterized by aberrant bone marrow plasma cell (PC) proliferation and is one of the most common hematological malignancies. The potential effect of cannabinoids on the immune system and hematological malignancies has been poorly characterized. Cannabidiol (CBD) may be used to treat various diseases. CBD is known to exert immunomodulatory effects through the activation of cannabinoid receptor 2 (CB2), which is expressed in high levels in the hematopoietic system. Cytokine-induced killer (CIK) cells are a heterogeneous population of polyclonal T lymphocytes obtained via ex vivo sequential incubation of peripheral blood mononuclear cells (PBMCs) with interferon-&gamma

https://doi.org/10.3390/ijms21113800